ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Asia300

US drug regulator finds violations at Sun Pharma's key plant

Indian drug maker says committed to promptly addressing FDA observations

The resolution of the Halol issue is crucial for the recovery of Sun Pharmaceutical's business in the U.S.   © Reuters

MUMBAI (NewsRise) -- Sun Pharmaceutical Industries, India's biggest drug maker by market value, said the U.S. drug regulator found three violations at its key plant in western India that was warned for breach of quality standards more than two years ago.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more